MIM
TCRX icon

Monashee Investment Management’s TScan Therapeutics TCRX Stock Holding History

Monashee Investment Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-400,000
Closed -$1M – 97
2023
Q2 		$1M Buy
+400,000
New +$1.07M 0.24% 57
2021
Q4 		– Sell
-100,000
Closed -$834K – 116
2021
Q3 		$834K Buy
+100,000
New +$927K 0.15% 122

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Monashee Investment Management's TCRX Position: Q3 2023 in Review

Monashee Investment Management sold out of TScan Therapeutics (TCRX) in Q3 2023, closing a stake of 400,000 shares — an estimated $1M sold.

Monashee Investment Management first reported a position in TCRX in Q3 2021 and held it in 2 quarters. The position peaked at $1M in Q2 2023. 32 funds tracked by Wall St. Rank hold TCRX as of Q3 2023.

  • Monashee Investment Management reported no remaining TScan Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Monashee Investment Management sold 400,000 TScan Therapeutics shares in Q3 2023, an estimated $1M.
  • Monashee Investment Management first reported a position in TScan Therapeutics in Q3 2021 and held it in 2 quarters.
  • Monashee Investment Management's TScan Therapeutics position peaked at $1M in Q2 2023.
  • 32 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2023.

Based on Monashee Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.